



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



LTI-291

Item No. 34305

CAS Registry No.: 1919820-28-2
Formal Name: 5,7-dimethyl-N-[*trans*-4-(pentyloxy)cyclohexyl]-pyrazolo[1,5-a]pyrimidine-3-carboxamide
MF: C₂₀H₃₀N₄O₂
FW: 358.5
Purity: ≥98%
UV/Vis.: λ_{max}: 224, 238 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LTI-291 is supplied as a solid. A stock solution may be made by dissolving the LTI-291 in the solvent of choice, which should be purged with an inert gas. LTI-291 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of LTI-291 in DMSO is approximately 20 mg/ml and approximately 30 mg/ml in ethanol and DMF.

LTI-291 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LTI-291 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. LTI-291 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LTI-291 is a CNS-penetrant allosteric activator of glucocerebrosidase (GCase).¹ It increases the activity of wild-type human GCase by 25 and 130% when used at concentrations of 0.1 and 1 μM, respectively.

Reference

1. den Heijer, J.M., Kruithof, A.C., van Amerongen, G., *et al.* A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator. *Br. J. Clin. Pharmac.* 1-13 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/22/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM